APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Vaccines & Therapeutics

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Selected research

Market Structure

Global mRNA Vaccines & Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025191 pages

Choose your research edition.

Industry ResearchmRNA Vaccines & Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Vaccines & Therapeutics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal mRNA Vaccines & Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Vaccines & Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Vaccines & Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.

This report provides an overview of the global mRNA Vaccines & Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of mRNA Vaccines & Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Vaccines & Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the mRNA Vaccines & Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

mRNA Vaccines & Therapeutics Segment by Company

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

mRNA Vaccines & Therapeutics Segment by Type

Infectious Disease Vaccines

Cancer Vaccines

mRNA Vaccines & Therapeutics Segment by Application

Infectious Disease

Cancer

mRNA Vaccines & Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. mRNA Vaccines & Therapeutics Industry Trends Table 2. mRNA Vaccines & Therapeutics Industry Drivers Table 3. mRNA Vaccines & Therapeutics Industry Opportunities and Challenges Table 4. mRNA Vaccines & Therapeutics Industry Restraints Table 5. Global mRNA Vaccines & Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global mRNA Vaccines & Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global mRNA Vaccines & Therapeutics Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global mRNA Vaccines & Therapeutics Sales Market Share by Manufacturers Table 9. Global mRNA Vaccines & Therapeutics Average Sales Price (USD/Doses) of Manufacturers (2021-2026) Table 10. Global mRNA Vaccines & Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global mRNA Vaccines & Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global mRNA Vaccines & Therapeutics Manufacturers, Product Type & Application Table 13. Global mRNA Vaccines & Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global mRNA Vaccines & Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Infectious Disease Vaccines Table 17. Major Manufacturers of Cancer Vaccines Table 18. Global mRNA Vaccines & Therapeutics Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 19. Global mRNA Vaccines & Therapeutics Sales by Type (2021-2026) & (M Doses) Table 20. Global mRNA Vaccines & Therapeutics Sales by Type (2027-2032) & (M Doses) Table 21. Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2021-2026) Table 22. Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2027-2032) Table 23. Global mRNA Vaccines & Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 24. Global mRNA Vaccines & Therapeutics Revenue by Type (2021-2026) & (M Doses) Table 25. Global mRNA Vaccines & Therapeutics Revenue by Type (2027-2032) & (M Doses) Table 26. Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2021-2026) Table 27. Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Infectious Disease Table 29. Major Manufacturers of Cancer Table 30. Global mRNA Vaccines & Therapeutics Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 31. Global mRNA Vaccines & Therapeutics Sales by Application (2021-2026) & (M Doses) Table 32. Global mRNA Vaccines & Therapeutics Sales by Application (2027-2032) & (M Doses) Table 33. Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2021-2026) Table 34. Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2027-2032) Table 35. Global mRNA Vaccines & Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global mRNA Vaccines & Therapeutics Revenue by Application (2021-2026) & (M Doses) Table 37. Global mRNA Vaccines & Therapeutics Revenue by Application (2027-2032) & (M Doses) Table 38. Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2021-2026) Table 39. Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2027-2032) Table 40. Global mRNA Vaccines & Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 41. Global mRNA Vaccines & Therapeutics Sales by Region (2021-2026) & (M Doses) Table 42. Global mRNA Vaccines & Therapeutics Sales Market Share by Region (2021-2026) Table 43. Global mRNA Vaccines & Therapeutics Sales Forecasted by Region (2027-2032) & (M Doses) Table 44. Global mRNA Vaccines & Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 45. North America mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 46. North America mRNA Vaccines & Therapeutics Sales by Country (2021-2026) & (M Doses) Table 47. North America mRNA Vaccines & Therapeutics Sales by Country (2027-2032) & (M Doses) Table 48. Europe mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 49. Europe mRNA Vaccines & Therapeutics Sales by Country (2021-2026) & (M Doses) Table 50. Europe mRNA Vaccines & Therapeutics Sales by Country (2027-2032) & (M Doses) Table 51. Asia Pacific mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 52. Asia Pacific mRNA Vaccines & Therapeutics Sales by Country (2021-2026) & (M Doses) Table 53. Asia Pacific mRNA Vaccines & Therapeutics Sales by Country (2027-2032) & (M Doses) Table 54. South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales by Country (2021-2026) & (M Doses) Table 56. South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales by Country (2027-2032) & (M Doses) Table 57. Global mRNA Vaccines & Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global mRNA Vaccines & Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 59. Global mRNA Vaccines & Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 60. Global mRNA Vaccines & Therapeutics Revenue Market Share by Region (2021-2026) Table 61. Global mRNA Vaccines & Therapeutics Revenue Market Share by Region (2027-2032) Table 62. Moderna Therapeutics Company Information Table 63. Moderna Therapeutics Business Overview Table 64. Moderna Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 66. Moderna Therapeutics Recent Development Table 67. CureVac Company Information Table 68. CureVac Business Overview Table 69. CureVac mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. CureVac mRNA Vaccines & Therapeutics Product Portfolio Table 71. CureVac Recent Development Table 72. Translate Bio Company Information Table 73. Translate Bio Business Overview Table 74. Translate Bio mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Translate Bio mRNA Vaccines & Therapeutics Product Portfolio Table 76. Translate Bio Recent Development Table 77. BioNTech Company Information Table 78. BioNTech Business Overview Table 79. BioNTech mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. BioNTech mRNA Vaccines & Therapeutics Product Portfolio Table 81. BioNTech Recent Development Table 82. Sangamo Therapeutics Company Information Table 83. Sangamo Therapeutics Business Overview Table 84. Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 86. Sangamo Therapeutics Recent Development Table 87. Argos Therapeutics Company Information Table 88. Argos Therapeutics Business Overview Table 89. Argos Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 91. Argos Therapeutics Recent Development Table 92. In-Cell-Art Company Information Table 93. In-Cell-Art Business Overview Table 94. In-Cell-Art mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio Table 96. In-Cell-Art Recent Development Table 97. eTheRNA Company Information Table 98. eTheRNA Business Overview Table 99. eTheRNA mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. eTheRNA mRNA Vaccines & Therapeutics Product Portfolio Table 101. eTheRNA Recent Development Table 102. Ethris Company Information Table 103. Ethris Business Overview Table 104. Ethris mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Ethris mRNA Vaccines & Therapeutics Product Portfolio Table 106. Ethris Recent Development Table 107. Tiba Biotechnology Company Information Table 108. Tiba Biotechnology Business Overview Table 109. Tiba Biotechnology mRNA Vaccines & Therapeutics Sales (M Doses), Price (USD/Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio Table 111. Tiba Biotechnology Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. mRNA Vaccines & Therapeutics Distributors List Table 115. mRNA Vaccines & Therapeutics Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. mRNA Vaccines & Therapeutics Product Image Figure 2. Global mRNA Vaccines & Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Vaccines & Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Vaccines & Therapeutics Sales (2021-2032) & (M Doses) Figure 5. Global mRNA Vaccines & Therapeutics Average Price (USD/Doses) & (2021-2032) Figure 6. Global Top 5 and 10 mRNA Vaccines & Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Infectious Disease Vaccines Image Figure 9. Cancer Vaccines Image Figure 10. Global mRNA Vaccines & Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 11. Global mRNA Vaccines & Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2021-2032) Figure 13. Global mRNA Vaccines & Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 14. Global mRNA Vaccines & Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2021-2032) Figure 16. Infectious Disease Image Figure 17. Cancer Image Figure 18. Global mRNA Vaccines & Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global mRNA Vaccines & Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2021-2032) Figure 21. Global mRNA Vaccines & Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global mRNA Vaccines & Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 25. North America mRNA Vaccines & Therapeutics Sales Market Share by Country (2021-2032) Figure 26. U.S. mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 27. Canada mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 28. Mexico mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 29. Europe mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 30. Europe mRNA Vaccines & Therapeutics Sales Market Share by Country (2021-2032) Figure 31. Germany mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 32. France mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. U.K. mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 34. Italy mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Netherlands mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Asia Pacific mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Asia Pacific mRNA Vaccines & Therapeutics Sales Market Share by Country (2021-2032) Figure 38. China mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 39. Japan mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. South Korea mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. Southeast Asia mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. India mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Australia mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales Market Share by Country (2021-2032) Figure 46. Brazil mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. South Africa mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. Saudi Arabia mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Turkey mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. Argentina mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. UAE mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. Egypt mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. Chile mRNA Vaccines & Therapeutics Sales and Growth Rate (2021-2032) & (M Doses) Figure 54. Global mRNA Vaccines & Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global mRNA Vaccines & Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America mRNA Vaccines & Therapeutics Revenue (2021-2032) & (US$ Million) Figure 57. North America mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe mRNA Vaccines & Therapeutics Revenue (2021-2032) & (US$ Million) Figure 59. Europe mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific mRNA Vaccines & Therapeutics Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. mRNA Vaccines & Therapeutics Value Chain Figure 65. Manufacturing Cost Structure Figure 66. mRNA Vaccines & Therapeutics Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Disease Vaccines
  • Cancer Vaccines
Applications
  • Infectious Disease
  • Cancer
Companies covered
  • Moderna Therapeutics
  • CureVac
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Vaccines & Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Vaccines & Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global mRNA Vaccines & Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global mRNA Vaccines & Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global mRNA Vaccines & Therapeutics Market Dynamics
  1. 2.1 mRNA Vaccines & Therapeutics Industry Trends
  2. 2.2 mRNA Vaccines & Therapeutics Industry Drivers
  3. 2.3 mRNA Vaccines & Therapeutics Industry Opportunities and Challenges
  4. 2.4 mRNA Vaccines & Therapeutics Industry Restraints
3 mRNA Vaccines & Therapeutics Market by Manufacturers
  1. 3.1 Global mRNA Vaccines & Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global mRNA Vaccines & Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global mRNA Vaccines & Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global mRNA Vaccines & Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global mRNA Vaccines & Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global mRNA Vaccines & Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global mRNA Vaccines & Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global mRNA Vaccines & Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 mRNA Vaccines & Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 mRNA Vaccines & Therapeutics Tier 1, Tier 2, and Tier 3
4 mRNA Vaccines & Therapeutics Market by Type
  1. 4.1 mRNA Vaccines & Therapeutics Type Introduction
  2. 4.1.1 Infectious Disease Vaccines
  3. 4.1.2 Cancer Vaccines
  4. 4.2 Global mRNA Vaccines & Therapeutics Sales by Type
  5. 4.2.1 Global mRNA Vaccines & Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global mRNA Vaccines & Therapeutics Sales by Type (2021-2032)
  7. 4.2.3 Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2021-2032)
  8. 4.3 Global mRNA Vaccines & Therapeutics Revenue by Type
  9. 4.3.1 Global mRNA Vaccines & Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global mRNA Vaccines & Therapeutics Revenue by Type (2021-2032)
  11. 4.3.3 Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2021-2032)
5 mRNA Vaccines & Therapeutics Market by Application
  1. 5.1 mRNA Vaccines & Therapeutics Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.2 Global mRNA Vaccines & Therapeutics Sales by Application
  5. 5.2.1 Global mRNA Vaccines & Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Vaccines & Therapeutics Sales by Application (2021-2032)
  7. 5.2.3 Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2021-2032)
  8. 5.3 Global mRNA Vaccines & Therapeutics Revenue by Application
  9. 5.3.1 Global mRNA Vaccines & Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global mRNA Vaccines & Therapeutics Revenue by Application (2021-2032)
  11. 5.3.3 Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2021-2032)
6 Global mRNA Vaccines & Therapeutics Sales by Region
  1. 6.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Vaccines & Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global mRNA Vaccines & Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global mRNA Vaccines & Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global mRNA Vaccines & Therapeutics Revenue by Region
  1. 7.1 Global mRNA Vaccines & Therapeutics Revenue by Region
  2. 7.1.1 Global mRNA Vaccines & Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global mRNA Vaccines & Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global mRNA Vaccines & Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global mRNA Vaccines & Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America mRNA Vaccines & Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe mRNA Vaccines & Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific mRNA Vaccines & Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Moderna Therapeutics
  2. 8.1.1 Moderna Therapeutics Company Information
  3. 8.1.2 Moderna Therapeutics Business Overview
  4. 8.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  6. 8.1.5 Moderna Therapeutics Recent Developments
  7. 8.2 CureVac
  8. 8.2.1 CureVac Company Information
  9. 8.2.2 CureVac Business Overview
  10. 8.2.3 CureVac mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CureVac mRNA Vaccines & Therapeutics Product Portfolio
  12. 8.2.5 CureVac Recent Developments
  13. 8.3 Translate Bio
  14. 8.3.1 Translate Bio Company Information
  15. 8.3.2 Translate Bio Business Overview
  16. 8.3.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Translate Bio mRNA Vaccines & Therapeutics Product Portfolio
  18. 8.3.5 Translate Bio Recent Developments
  19. 8.4 BioNTech
  20. 8.4.1 BioNTech Company Information
  21. 8.4.2 BioNTech Business Overview
  22. 8.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BioNTech mRNA Vaccines & Therapeutics Product Portfolio
  24. 8.4.5 BioNTech Recent Developments
  25. 8.5 Sangamo Therapeutics
  26. 8.5.1 Sangamo Therapeutics Company Information
  27. 8.5.2 Sangamo Therapeutics Business Overview
  28. 8.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  30. 8.5.5 Sangamo Therapeutics Recent Developments
  31. 8.6 Argos Therapeutics
  32. 8.6.1 Argos Therapeutics Company Information
  33. 8.6.2 Argos Therapeutics Business Overview
  34. 8.6.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  36. 8.6.5 Argos Therapeutics Recent Developments
  37. 8.7 In-Cell-Art
  38. 8.7.1 In-Cell-Art Company Information
  39. 8.7.2 In-Cell-Art Business Overview
  40. 8.7.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio
  42. 8.7.5 In-Cell-Art Recent Developments
  43. 8.8 eTheRNA
  44. 8.8.1 eTheRNA Company Information
  45. 8.8.2 eTheRNA Business Overview
  46. 8.8.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 eTheRNA mRNA Vaccines & Therapeutics Product Portfolio
  48. 8.8.5 eTheRNA Recent Developments
  49. 8.9 Ethris
  50. 8.9.1 Ethris Company Information
  51. 8.9.2 Ethris Business Overview
  52. 8.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ethris mRNA Vaccines & Therapeutics Product Portfolio
  54. 8.9.5 Ethris Recent Developments
  55. 8.10 Tiba Biotechnology
  56. 8.10.1 Tiba Biotechnology Company Information
  57. 8.10.2 Tiba Biotechnology Business Overview
  58. 8.10.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio
  60. 8.10.5 Tiba Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 mRNA Vaccines & Therapeutics Value Chain Analysis
  2. 9.1.1 mRNA Vaccines & Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 mRNA Vaccines & Therapeutics Production Mode & Process
  6. 9.2 mRNA Vaccines & Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 mRNA Vaccines & Therapeutics Distributors
  9. 9.2.3 mRNA Vaccines & Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst